Warmuth Markus 4

What Happened Markus Warmuth, President & CEO and a director of Monte Rosa Therapeutics (GLUE), sold a total of 5,466 shares in open-market transactions on June 1, 2026, generating about $106,253 in proceeds. The filing reports two disposals: 4,998 shares at a weighted average price of $19.41 (proceeds $97,021) and 468 shares at a weighted average price of $19.73 (proceeds $9,232). These were sales (not purchases), which are often routine dispositions.

Key Details

• Transaction date (period reported): June 1, 2026; Form 4 filed: June 2, 2026 (timely).
• Reported amounts: 4,998 shares @ $19.41 = $97,021; 468 shares @ $19.73 = $9,232; total ≈ $106,253.
• Footnotes: Transactions were executed under a Rule 10b5-1 trading plan adopted May 14, 2025 (F1). The reported prices are weighted averages; the filings note trades occurred across price ranges of $18.69–$19.68 (F2) and $19.69–$19.77 (F3). The reporting person will provide per-price breakdowns on request.
• Shares owned after the transactions: not specified in the supplied details (refer to the Form 4 for post-transaction holdings).
• Filing timeliness: filed the next day (no late-filing flag indicated).

Context

• Sales under a pre-established 10b5-1 plan are structured trading arrangements that allow insiders to sell shares according to a pre-set schedule; they do not, by themselves, indicate a change in the insider’s view of the company.
• For retail investors, purchases by insiders can be more meaningful as a bullish signal; routine programmatic sales like these are common and often relate to diversification or liquidity needs rather than company-specific news.